New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2013
09:35 EDTTWTR, AAPL, MA, GILD, TSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA GILD MA TWTR GOOG
News For AAPL;TSLA;MA;TWTR;GILD From The Last 14 Days
Check below for free stories on AAPL;TSLA;MA;TWTR;GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
April 11, 2014
05:41 EDTTSLASQM upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill upgraded SQM (SQM) to Neutral citing the bottoming of potash prices and improving demand for lithium after Tesla (TSLA) announced plans to build a factory to produce batteries for electric cars. The firm raised its price target for shares to $34 from $25.
05:25 EDTGILDGilead announces 95% virologic suppression in HCV study
Gilead Sciences announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi 400 mg was administered for the treatment of chronic hepatitis C virus infection in patients with advanced liver disease. The first study, Study GS-US-334-0125, is an ongoing open-label Phase 2 clinical trial evaluating HCV patients with cirrhosis and portal hypertension, with or without decompensation, who were randomized 1:1 to an immediate treatment arm in which Sovaldi and ribavirin was administered for 48 weeks or to a deferred treatment arm in which this regimen was initiated after a 24-week observation period. Eighty percent of participants were treatment-experienced. Of the 22 patients who completed 24 weeks of therapy, 95% achieved virologic suppression on treatment. Additionally, patients taking Sovaldi-based therapy experienced trends in clinical and laboratory parameter improvements compared to patients in the observation arm. Sovaldi-based therapy was well tolerated in the study, and only one patient discontinued treatment due to an adverse event. The most common adverse events occurring in more than 25 percent of patients included nausea and pruritis.
April 10, 2014
16:00 EDTAAPL, TSLAOptions Update; April 10, 2014
Subscribe for More Information
13:12 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
11:44 EDTGILDStocks with call strike movement; PCLN GILD
Subscribe for More Information
11:42 EDTGILDReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
10:00 EDTAAPLOn The Fly: Analyst Initiation Summary
Apple (AAPL) initiated with a Buy at Deutsche Bank... Crocs (CROX) initiated with a Buy at Buckingham... Deckers Outdoor (DECK) initiated with a Buy at Buckingham... EMC (EMC) initiated with a Buy at Deutsche Bank... HP (HPQ) initiated with a Buy at Deutsche Bank... IBM (IBM) initiated with a Hold at Deutsche Bank... NeoPhotonics (NPTN) coverage resumed with a Market Perform at Raymond James... NetApp (NTAP) initiated with a Hold at Deutsche Bank... Nutrisystem (NTRI) initiated with a Buy at B. Riley... Questar (STR) initiated with an Underperform at BofA/Merrill... S&T Bancorp (STBA) initiated with an Outperform at Raymond James... STB Systems Inc (STBI) initiated with an Outperform at Raymond James... Skechers (SKX) initiated with an Underperform at Buckingham... Steven Madden (SHOO) initiated with a Buy at Buckingham... UGI Corporation (UGI) initiated with a Buy at BofA/Merrill... Web.com (WWWW) initiated with a Neutral at Buckingham... Ally Financial (ALLY) initiated with a Buy at BTIG... Visteon (VC) initiated with a Buy at Citigroup... Greatbatch (GB) initiated with a Buy at KeyBanc... Steris (STE) initiated with a Buy at KeyBanc... Cooper Companies (COO) initiated with a Hold at KeyBanc... Hill-Rom (HRC) initiated with a Hold at KeyBanc... Invacare (IVC) initiated with a Hold at KeyBanc... Teleflex (TFX) initiated with a Hold at KeyBanc... Provident Financial (PROV) initiated with a Market Perform at Keefe Bruyette... UMH Properties (UMH) initiated with a Hold at Wunderlich.
10:00 EDTTWTROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:37 EDTTSLA, AAPLActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
08:22 EDTAAPLApple seen offering iWatches priced as high as 'thousands,' AppleInsider says
KGI analyst Ming-Chi Kuo, who has a proven track record of predicting about Apple hardware, predicts that one of the major differences between Apple's smartwatch and those from rivals will be that its casing and band will come in a variety of materials and that luxury iWatches will carry a price tag of "several thousand dollars," reported AppleInsider. Other features expected by Kuo for the device, including biometrics, a flexible AMOLED display with sapphire cover lens and NFC, the report added. Reference Link
08:12 EDTTSLATesla's Musk to kick-off China debut this month, Bloomberg says
Tesla Motors is planning to begin offering its luxury sedans in China this month and said the companyĺs co-founder, Elon Musk, will be in the country to kick-off the debut, according to Bloomberg, citing comments from Tesla's vice president of marketing and communications. Reference Link
07:39 EDTAAPLApple Chief Designer gains more say over software, Bloomberg says
Subscribe for More Information
07:38 EDTTSLATesla has some potential volume upside for Model X, says Goldman
Subscribe for More Information
07:24 EDTAAPLApple may release 12" Retina MacBook Air, low price iMac in 2014, MacRumors says
Subscribe for More Information
07:24 EDTGILDInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
06:48 EDTAAPLApple initiated with a Buy at Deutsche Bank
Deutsche Bank believes the iPhone and iPad offer good growth for Apple with upside coming from the potential for a larger screen sized phone. The firm initiated the stock with a Buy rating and $650 price target.
06:41 EDTAAPLApple confirms Christie departure, FT reports
Subscribe for More Information
06:33 EDTTWTRTwitter upgraded to Hold from Sell at Cantor
Cantor Fitzgerald upgraded its rating on Twitter (TWTR) shares to Hold from Sell citing the recent pullback in the stock as well as the upcoming launch of new ad formats which it believes should drive monetization. Cantor maintains a $45 price target for the stock and says it continues to prefer Facebook (FB). Shares of Twitter closed yesterday up 71c to $42.49.
05:37 EDTGILDGilead announces Phase 2 results for investigational sofosbuvir-based regimens
Gilead Sciences announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, for the treatment of chronic hepatitis C virus, or HCV, infection. The first study, ELECTRON2, is an ongoing, open-label Phase 2 clinical trial evaluating a once-daily fixed-dose combination of SOF 400 mg and the NS5A inhibitor ledipasvir, or LDV, 90 mg, with and without ribavirin, or RBV, twice-daily, among HCV-infected patient populations. In this study, 100% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF plus RBV and 64% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF without RBV achieved a sustained virologic response 12 weeks after completing therapy. Among genotype 1-infected patients who had failed prior treatment with SOF plus RBV, 100% achieved SVR12 following 12 weeks of LDV/SOF plus RBV. Additionally, 65% of genotype 1-infected patients with decompensated or Child-Turcotte-Pugh Class B cirrhosis receiving 12 weeks of LDV/SOF without RBV achieved SVR12. LDV/SOF with and without RBV was well-tolerated, including among patients with more advanced liver disease. A second study, Study GS-US-342-0102, is an ongoing randomized Phase 2 clinical trial in which treatment-na´ve, non-cirrhotic patients with genotypes 1-6 HCV infection received a 12-week course of SOF plus the pan-genotypic NS5A inhibitor GS-5816. Patients received SOF 400 mg and either GS-5816 25 mg or GS-5816 100 mg. In this study, 94.8% of patients receiving the 25 mg dose of GS-5816 and 96.1% of patients receiving the 100 mg dose achieved SVR12.
05:32 EDTGILDGilead announces results from study of Sovaldi
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use